One of the two big buzzes in the genomics business world was the announcement that Roche Diagnostics has signed a major deal with Pacific Biosciences in the field of human diagnostics, which comes with a $35M upfront payment and a possible $45M in milestones, plus future sales of reagents. PacBio stock rocketed over 70% on this news. This on the same day that cancer diagnostics company Foundation Medicine went public with a similar potent climb from their offering price; a good day for those lucky enough to have the shares (which, by the way, does not include me in any way, though Foundation shares a common venture backer with Warp Drive Bio in Third Rock Ventures).
A computational biologist's personal views on new technologies & publications on genomics & proteomics and their impact on drug discovery
Thursday, September 26, 2013
Monday, September 23, 2013
Potential Sources of Drag on PacBio's Long Read Performance Trajectory
Over at Homolog.us there are two detailed blog entries on Pacific Biosciences entitled "End of Short Read Era?" (Part I and Part II). I've tweeted a number of comments on the technical aspects, but there are some more substantial thoughts reading these pieces helped me condense.
Subscribe to: Posts (Atom)